BioNTech SE - ADR vs Prospect Capital Corporation — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while Prospect Capital Corporation trades at $2.27 (market cap $1.15B). The key difference: BioNTech SE - ADR is far larger — about 20.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.83% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PSEC | |
|---|---|---|
Market Cap | $23.31B | $1.15B |
Sector | Health | Financials |
52-Week High | $119.34 | $3.05 |
52-Week Low | $83.89 | $2.11 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 21.83% |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
PSEC trades at $2.33, up 5.43% in the last session, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals, with a low P/B of 0.4 and recent quarterly EPS beats, but negative revenue and net income in 2025. Recent news highlights a dividend increase for an affiliate fund and the sale of Valley Electric for a 4.8x return.
Outlook is cautious; the stock offers value with a low P/B and dividend yield, but significant risks include persistent negative profitability, high P/S ratio, and analyst skepticism. Investment appeal hinges on portfolio turnaround and sustained dividend stability amid operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →